Preclinical Imaging (In-VIVO) Market - Forecast(2021 - 2026)

Report Code: HCR 0532 Report Format: PDF + Excel (Delivery in 48 Hrs)
Preclinical Imaging (In-VIVO) Market Overview
Preclinical Imaging (In-VIVO) Market size is estimated to reach $983.6 Million by 2025, growing at a CAGR of 5.47% during the forecast period 2020-2025. Preclinical Imaging is the research process done on living organisms for the drug development. This Preclinical In-VIVO imaging is used to study the changes at different stages, that is at the organ, tissue, and molecular level, using different types of modalities. The longitudinal study of drug development by disease monitoring and its therapeutic response by In-vivo imaging is set to have a major impact. The increase in cancers, cardiovascular and other diseases among people and an increase in the usage of preclinical in-vivo imaging techniques for the development of medicines and treatment to cure those diseases is driving the market. 

Preclinical Imaging (In-VIVO) Market Report Coverage
The report: “Preclinical Imaging (In-VIVO) Market Forecast (2020-2025)”, by Industry ARC, covers an in-depth analysis of the following segments of the Preclinical Imaging (In-VIVO) Market. 

By Modality Type: Micro-Ultrasound, Micro Magnetic Resonance imaging (MRI), Micro Computed Tomography (CT), Optical Imaging, Positron Emission Tomography (PET), Single Photo Emission Computed Tomography (SPECT), Photo-acoustic Imaging systems, Magnetic Particle Imaging (MPI) systems.
By Reagent: Optical Imaging Reagents, Nuclear Imaging Reagents, Preclinical MRI Contrast Agents, Preclinical Ultrasound Contrast Agents, Preclinical CT Contrast Agents and Others.
By Application: Drug discovery, Bio-distribution, Cancer cell detection, Bio-markers, Research and development.
By Geography: North America, Asia-Pacific, Europe, Rest of World.

Key Takeaways
  • Geographically, North America’s Preclinical Imaging (In-VIVO) Market accounted for the highest revenue share in 2019 and it is poised to dominate during the forecast period 2020-2025 owing to the high usage of different modalities in research and development.
  • Advancement in new technologies and increased usage of different types of modalities together for better and fast results is boosting the market.
  • Detailed analysis on the Strength, Weakness and Opportunities of the prominent players operating in the market will be provided in the Preclinical Imaging Market report.
  • Increase in chronic diseases like cancer, cardiovascular, neurological disorders and other diseases are set to increase the growth of the preclinical imaging market during the forecast period 2020-2025.

By Modality Type - Segment Analysis
The global Preclinical Imaging (In-VIVO) Market based on modality type has Micro-Ultrasound, Micro Magnetic Resonance imaging (MRI), Micro Computed Tomography (CT), Optical Imaging, Positron Emission Tomography (PET), Single Photo Emission Computed Tomography (SPECT), Photo-acoustic Imaging systems, Magnetic Particle Imaging (MPI) systems. Micro Ultrasound has a dominant role during the year 2019 and is set to have the fastest growth during the forecast period 2020-2025, owing to the wide ranges of application and most effective to make researches on the small animal models. The other modalities like Micro-CT and Optical Imaging are also set to have the fastest growth owing to the increase in usage of these modalities and the advancement of the latest technologies in these segments.

By Application - Segment Analysis
The Application segment of Preclinical Imaging (In-VIVO) Market has Drug discovery, Bio-distribution, Cancer cell detection, Bio-markers, Research and development. The research and development section has a dominant role in the year 2019 and is set have the fastest growth during the forecast period 2020-2025 owing to the increased usage of the modalities for the research and development of different types of drugs and treatments. The increase in chronic diseases and the adoption of the preclinical in-vivo imaging in cancer cell detection and drug discovery is boosting the market. 

By Geography - Segment Analysis
The global Preclinical Imaging (In-VIVO) Market by geography had the dominant share in North America, in terms of revenue in 2019. North America holds the largest market share owing to the increase in installation of the modalities for research and development of treatment process and drug development. The Europe is also set to grow during the forecast period 2020-2025 owing to the increase in new technology and increased funding by the government and private sectors for the research. Favorable growth and increased chronic diseases among the people and having the best infrastructure for research and development are some of the factors supporting the growth of this market around the globe.

Drivers – Preclinical Imaging (In-VIVO) Market
  • Increased usage of Preclinical Imaging in different sectors
The demand for preclinical in-vivo imaging modalities in different fields like research and development, drug discovery, cancer cell detection and other are boosting the market of preclinical in-vivo imaging. The increase in funding by the private and public sectors are also driving the market. Adaption of new technologies and acquisitions made by different market players in different players of the world are supporting the growth of the market.

Challenges – Preclinical Imaging (In-VIVO) Market
  • High cost of modalities
The high price of modalities and the cost of the research processes are limiting many of the institutes to adopt this preclinical in-vivo imaging process. Limited application of different modalities is another factor challenging market growth.

Preclinical Imaging (In-VIVO) Industry outlook:
Product launches, mergers and acquisitions, joint ventures, and geographical expansions are key strategies adopted by players in the Preclinical Imaging (In-VIVO) Market. Key companies of this market are PerkinElmer, Inc., Siemens A.G, Bruker Corporation, FUJIFILM Holdings Corporation, Mediso Ltd., MILabs B.V., Agilent Technologies, Miltenyi Biotech GmbH, Aspect Imaging, TriFoil Imaging, and others.

Acquisitions/Product Launches:
  • In February 2017, FUJIFILM VisualSonics Inc, announced the launch of new Vevo LAZR-X, which uses high-frequency ultrasound and photoacoustic imaging techniques together for the animal research application.
  • In February 2019, Bruker announced the new Skyscan 1273 benchtop 3D x-ray microscope based on micro-CT technology, this is used for the non-destructive 3D imaging, covering a variety of industrial and scientific application.

1. Preclinical Imaging (In-VIVO) Market - Overview
    1.1 Definitions and Scope
2. Preclinical Imaging (In-VIVO) Market - Executive Summary
    2.1 Market Revenue and Key Trends by Company
    2.2 Key trends by Modality type
    2.3 Key trends by Reagent
    2.4 Key trends by Application
    2.5 Key trends by Geography
3. Preclinical Imaging (In-VIVO) Market – Comparative Analysis
    3.1 Product Benchmarking – Key Companies
    3.2 Financial Analysis – Key Companies
    3.3 Market Value Split by Key Companies 
    3.4 Patent Analysis – Key Companies
    3.5 Pricing Analysis
4. Preclinical Imaging (In-VIVO) Market - Startup Companies Scenario (Premium)
    4.1 Key Startup Company Analysis by
        4.1.1 Investment
        4.1.2 Revenue
        4.1.3 Venture Capital and Funding Scenario
5. Preclinical Imaging (In-VIVO) Market – Industry Market Entry Scenario Premium (Premium)
    5.1 Regulatory Framework Overview
    5.2 New Business and Ease of Doing business index
    5.3 Case Studies of Successful Ventures
6. Preclinical Imaging (In-VIVO) - Market Forces
    6.1 Market Drivers
    6.2 Market Constraints/Challenges
    6.3 Porters five force model
        6.3.1 Bargaining power of suppliers
        6.3.2 Bargaining powers of customers
        6.3.3 Threat of new entrants
        6.3.4 Rivalry among existing players
        6.3.5 Threat of substitutes 
7. Preclinical Imaging (In-VIVO) Market – Strategic Analysis
    7.1 Value Chain Analysis
    7.2 Opportunities Analysis
    7.3 Market Life Cycle
8. Preclinical Imaging (In-VIVO) Market – By Modality Type (Market Size –$Million/$Billion)
    8.1 Micro-Ultrasound
    8.2 Micro Magnetic Resonance imaging (MRI)
    8.3 Micro Computed Tomography (CT)
    8.4 Optical Imaging
    8.5 Positron Emission Tomography (PET)
    8.6 Single Photo Emission Computed Tomography (SPECT)
    8.7 Photo-acoustic Imaging systems
    8.8 Magnetic Particle Imaging (MPI) systems.
9. Preclinical Imaging (In-VIVO) Market – By Reagent (Market Size –$Million/$Billion)
    9.1 Optical Imaging Reagents
        9.1.1 Fluorescent Imaging Reagents
        9.1.2 Bio-luminescent Imaging Reagents
    9.2 Nuclear Imaging Reagents
        9.2.1 Preclinical SPECT Probes, 
        9.2.2 Preclinical PET Tracers, 
    9.3 Preclinical MRI Contrast Agents, 
    9.4 Preclinical Ultrasound Contrast Agents, 
    9.5 Preclinical CT Contrast Agents
    9.6 Others
10. Preclinical Imaging (In-VIVO) Market – By Application (Market Size –$Million/$Billion)
    10.1 Drug discovery
    10.2 Bio-distribution
    10.3 Cancer cell detection
    10.4 Bio-markers
    10.5 Research and development
11. Preclinical Imaging (In-VIVO) Market - By Geography (Market Size –$Million/$Billion)
    11.1 North America
        11.1.1 U.S.
        11.1.2 Canada
        11.1.3 Mexico
    11.2 Europe
        11.2.1 U.K.
        11.2.2 Germany
        11.2.3 France
        11.2.4 Italy
        11.2.5 Spain
        11.2.6 Rest of Europe
    11.3 Asia-Pacific
        11.3.1 China
        11.3.2 India
        11.3.3 Japan
        11.3.4 South Korea
        11.3.5 Australia & New Zealand
        11.3.6 Rest of Asia-Pacific
    11.4 Rest of the World
        11.4.1 Middle East
        11.4.2 Africa
        11.4.3 South America
12. Preclinical Imaging (In-VIVO) Market - Entropy
13. Preclinical Imaging (In-VIVO) Market – Industry/Segment Competition Landscape   (Premium) 
    13.1 Market Share Analysis
        13.1.1 Global Market Share – Key Companies
        13.1.2 Market Share by Region – Key companies
        13.1.3 Market Share by Countries – Key Companies
        13.1.4 Best Practices for Companies
14. Preclinical Imaging (In-VIVO) Market – Key Company List by Country Premium (Premium)
15. Preclinical Imaging (In-VIVO) Market Company Analysis
    15.1 Company 1
    15.2 Company 2
    15.3 Company 3
    15.4 Company 4
    15.5 Company 5
    15.6 Company 6
    15.7 Company 7
    15.8 Company 8
    15.9 Company 9
    15.10 Company 10 and more
"*Financials for private companies would be provided on a best efforts basis”.